Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination

Affiliations

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Conn; Department of Pathology, Yale University School of Medicine, New Haven, Conn. Electronic address: mary.tomayko@yale.edu.
² Department of Dermatology, Yale University School of Medicine, New Haven, Conn; Department of Pathology, Yale University School of Medicine, New Haven, Conn.
³ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.
⁴ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Harvard Medical School, Boston, Mass.
⁵ Department of Dermatology, Yale University School of Medicine, New Haven, Conn.
⁶ Anne Arundel Dermatology, Fairfax, Va.
⁷ HVMA/Atrius Health, Peabody, Mass.
⁸ Cedars-Sinai Medical Group, Department of Dermatology, Beverly Hills, Calif.
⁹ Department of Dermatology, University of California, San Francisco, Calif.
¹⁰ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Mary M Tomayko et al. J Allergy Clin Immunol. 2021 Sep.

. 2021 Sep;148(3):750-751.

doi: 10.1016/j.jaci.2021.06.026. Epub 2021 Jul 15.

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Conn; Department of Pathology, Yale University School of Medicine, New Haven, Conn. Electronic address: mary.tomayko@yale.edu.
² Department of Dermatology, Yale University School of Medicine, New Haven, Conn; Department of Pathology, Yale University School of Medicine, New Haven, Conn.
³ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.
⁴ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Harvard Medical School, Boston, Mass.
⁵ Department of Dermatology, Yale University School of Medicine, New Haven, Conn.
⁶ Anne Arundel Dermatology, Fairfax, Va.
⁷ HVMA/Atrius Health, Peabody, Mass.
⁸ Cedars-Sinai Medical Group, Department of Dermatology, Beverly Hills, Calif.
⁹ Department of Dermatology, University of California, San Francisco, Calif.
¹⁰ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

No abstract available

References

1. McMahon D.E., Amerson E., Rosenbach M., Lipoff J.B., Moustafa D., Tyagi A. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46–55. - PMC - PubMed
1. Kridin K., Ludwig R.J. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 2018;5:220. - PMC - PubMed
1. Kasperkiewicz M, Woodley DT. Association between vaccination and autoimmune bullous diseases: a systematic review. J Am Acad Dermatol . Accessed April 24, 2021. - DOI - PubMed
1. de la Fuente S., Hernandez-Martin A., de Lucas R., Gonzalez-Ensenat M.A., Vicente A., Colmenero I. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol. 2013;30:741–744. - PubMed
1. Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279. - PMC - PubMed